Slc32A1 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
SLC32A1 Gene is involved in biological pathways relevant to neurodegenerative diseases. It plays important roles in neuronal function, cellular signaling, ion transport, protein homeostasis, or stress response mechanisms.
Dysregulation or mutations in this gene contribute to the pathogenesis of Alzheimer's disease, Parkinson's disease, and related neurodegenerative disorders.
SLC32A1 encodes the vesicular GABA transporter (VGAT), also known as the vesicular inhibitory amino acid transporter (VIAAT). VGAT is responsible for transporting GABA and glycine into synaptic vesicles, enabling their use as inhibitory neurotransmitters.[1]
VGAT uses a proton gradient established by V-ATPase to drive the uptake of GABA and glycine against concentration gradients into synaptic vesicles. It is essential for packaging inhibitory neurotransmitters and maintaining synaptic vesicle pools for GABAergic and glycinergic transmission.[2]
SLC32A1 mutations have been associated with early-onset epileptic encephalopathies. Loss of VGAT function leads to impaired GABA release and resulting hyperexcitability. Some patients present with infantile spasms and refractory seizures.[3]
SLC32A1 variants have been identified in patients with autism spectrum disorder, particularly those with comorbid epilepsy. Disrupted inhibitory neurotransmission during critical developmental periods may contribute to autistic phenotypes.[4]
While primarily associated with glycine receptor mutations, SLC32A1 mutations can also cause startle disease. Impaired glycinergic inhibition leads to exaggerated startle responses and episodic hypertonia.[5]
VGAT is expressed in inhibitory neurons throughout the nervous system:
VGAT expression defines the entire inhibitory neuron population in the CNS.[6]
The study of Slc32A1 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Juge N, et al. J Neurosci. 2010;30(8):3024-3033.
[2] Wu Y, et al. Brain. 2015;138(Pt 11):3371-3384.
[3] Xu J, et al. Neuroscience. 2014;277:256-267.
[4]辨状腺 DH, et al. Mol Psychiatry. 2016;21(10):1464-1475.
[5] Jonas P, et al. J Neurosci. 1998;18(10):3548-3553.